Valeant to acquire Bausch + Lomb for $8.7 billion

Valeant Pharmaceuticals has agreed to purchase Bausch + Lomb for $8.7 billion in cash, according to a joint news release from the companies.Under the agreement, Bausch + Lomb will keep its name and function as a division of Valeant, and Valeant’s ophthalmology holdings will be folded into the Bausch + Lomb division, the release said.

Full Story →